Who are Evaxion A/S's main suppliers?

Evaxion A/S (EVAX) key suppliers include: PHARMAJET-INC, STATENS-SERUM-INSTITUT, BioNTech SE, BioNTech SE, Johnson & Johnson and 5 more. View the full supplier network at chainsifter.com/chain/EVAX.

Who are Evaxion A/S's major customers?

Evaxion A/S (EVAX) key customers include: BioNTech SE, BioNTech SE, Johnson & Johnson, Johnson & Johnson, Merck & Co., Inc. and 7 more. View the full customer network at chainsifter.com/chain/EVAX.

What sector is Evaxion A/S in?

Evaxion A/S (EVAX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Evaxion A/S Suppliers, Customers & Supply Chain (EVAX)

10Suppliers

12Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Evaxion A/S (EVAX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

24Total relationships

3Distinct source URLs

4High confidence

0.742Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Evaxion A/S Suppliers

Ticker	Name	Confidence	Evidence
PHARMAJET-INC	PHARMAJET-INC	90%	We have entered into license agreements, including with Statens Serum Institut (SSI) and PharmaJet, Inc., to obtain rights to intellectual property useful for pharmaceutical formulations and delivery…
STATENS-SERUM-INSTITUT	STATENS-SERUM-INSTITUT	90%	We have entered into license agreements, including with Statens Serum Institut (SSI) and PharmaJet, Inc., to obtain rights to intellectual property useful for pharmaceutical formulations and delivery…
BNTX	BioNTech SE	72%	g Phase 2b trial, we are required to pay to SSI a percentage of any sublicensing income in the mid double-digit range. Prior to any out-licensing or commercialization of EVX-01, we are not required t…
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: g Phase 2b trial, we are required t…
JNJ	Johnson & Johnson	72%	g Phase 2b trial, we are required to pay to SSI a percentage of any sublicensing income in the mid double-digit range. Prior to any out-licensing or commercialization of EVX-01, we are not required t…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: g Phase 2b trial, we are required to pay to SSI a percentage of any sublicensing income in the mid double-digit range.…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: The Chief Operating Officer joined the Company on March 14, 2022 and the Chief Financial Officer is expected to join t…
MRK	Merck & Co., Inc.	72%	The Chief Operating Officer joined the Company on March 14, 2022 and the Chief Financial Officer is expected to join the Company in August 2022. Russia’s Invasion of Ukraine On February 24, 2022, Rus…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: g Phase 2b trial, we are required…
SNYNF	Sanofi	72%	g Phase 2b trial, we are required to pay to SSI a percentage of any sublicensing income in the mid double-digit range. Prior to any out-licensing or commercialization of EVX-01, we are not required t…

Evaxion A/S Customers

Ticker	Name	Confidence	Evidence
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In…
BNTX	BioNTech SE	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
JNJ	Johnson & Johnson	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a resul…
MRK	Merck & Co., Inc.	72%	bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable markets and unfavorable market conditions, …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clin…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from NVO graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from NVO grap…
NVO	Novo Nordisk A/S	72%	of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly, time-consuming, and disruptive to our operations. Any claims or litigation, eve…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. I…
SNYNF	Sanofi	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
PASSIVE-FOREIGN-INVESTMENT-COMPANY	PASSIVE-FOREIGN-INVESTMENT-COMPANY	62%	ormation only and does not purport to constitute tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. T…
SUBSIDIARY-SHARES-GROUP	SUBSIDIARY-SHARES-GROUP	62%	ormation only and does not purport to constitute tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. T…

Evaxion A/S Debt Obligations

Instrument	Description	Confidence	Evidence
EVAX-DEBT	Debt stack $7.5M	90%	Market cache reports total debt of $7.5M.

Evaxion A/S Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Evaxion A/S.

Evaxion A/S Ownership

Holder	Name	Confidence	Evidence
EVAX-OWNER-IKARIAN-CAPITAL-LLC	Ikarian Capital, LLC	90%	13F overlay lists Ikarian Capital, LLC as top holder; 16 tracked holders.

Evaxion A/S Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BMY	Bristol-Myers Squibb Company	100.00	2
IBRX	ImmunityBio, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
BNTX	BioNTech SE	100.00	1	['customer', 'supplier']
PSNL	Personalis, Inc.	100.00	2
HIMS	Hims & Hers Health, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
ENLV	Enlivex Ltd.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
NVO	Novo Nordisk A/S	100.00	1	['customer']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
IBIO	iBio, Inc.	100.00	2

Evaxion A/S Supply Chain